Lead Sponsor

Bristol-Myers Squibb

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

No

•Participants with confirmed diagnosis of unresectable or metastatic cutaneous melanoma, or stage IIB-IV cutaneous melanoma who have undergone complete resection
•Initiated treatment with nivolumab monotherapy or in combination with ipilimumab for unresectable or metastatic melanoma, or as adjuvant therapy for resected stage IIb-IV melanoma, between January 1, 2015 and 6 months prior to data collection
•For the adjuvant nivolumab cohort, initiated treatment with nivolumab for stage IIb-IV melanoma within 12 weeks following index resection
•Aged \<18 years at the time of nivolumab/ipilimumab treatment initiation
•At least 6 months of follow-up from index treatment date (unless deceased prior to end of 6 months)

•Prior malignancy active within 3 years prior to nivolumab or ipilimumab treatment index date except for locally curable cancers that have been apparently cured (such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast)
•Receiving nivolumab therapy (monotherapy, combination with ipilimumab, or adjuvant therapy) for melanoma as part of a clinical trial during the study period

Related studies

NCT06961357 · Melanoma

NCT07379138 · Melanoma

NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more

NCT04855435 · Advanced Solid Tumor, Uveal Melanoma, Metastatic, and more

NCT05076760 · Solid Tumor, Advanced Cancer, and more

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma